Update on aurora kinase targeted therapeutics in oncology

Author： Green Myke R   Woolery Joseph E   Mahadevan Daruka  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.6, Iss.3, 2011-03, pp. : 291-307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aurora kinase targeted therapeutics in oncology: past, present and future

By Mahadevan Daruka   Beeck Sunni  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 7, 2007-07 ,pp. : 1011-1026

Informa Healthcare

Access to resources Recommend Favorite

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 –– 10)

By Cheung Chun Hei Antonio   Coumar Mohane Selvaraj   Chang Jang-Yang   Hsieh Hsing-Pang  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 857-884

Informa Healthcare

Access to resources Recommend Favorite

Danusertib, an aurora kinase inhibitor

By Meulenbeld Hielke J   Mathijssen Ron HJ   Verweij Jaap   de Wit Ronald   de Jonge Maja JA  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 383-393

Informa Healthcare

Access to resources Recommend Favorite

The emergence of resistance to targeted cancer therapeutics

By Mellinghoff Ingo K   Sawyers Charles L  

Pharmacogenomics, Vol. 3, Iss. 5, 2002-09 ,pp. : 603-623

Future Medicine

Access to resources Recommend Favorite

Bcl-2-targeted cancer therapeutics

By Khorchid Amani   Beauparlant Pierre  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 6, 2004-06 ,pp. : 805-818

Informa Healthcare

Access to resources Recommend Favorite